Profound Medical (PROF)
(Delayed Data from NSDQ)
$8.01 USD
-0.19 (-2.32%)
Updated Sep 9, 2024 03:59 PM ET
After-Market: $8.01 0.00 (0.00%) 7:10 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for Profound Medical falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 7 | 7 | 7 | 7 | 4 |
Cost Of Goods | 3 | 4 | 4 | 4 | 2 |
Gross Profit | 4 | 3 | 3 | 3 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 33 | 35 | 33 | 22 | 17 |
Income After Depreciation & Amortization | -29 | -32 | -30 | -19 | -15 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | -4 | 0 | 3 | 1 |
Pretax Income | -29 | -28 | -31 | -22 | -15 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -29 | -29 | -31 | -22 | -15 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -29 | -29 | -31 | -22 | -15 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -27 | -31 | -28 | -17 | -13 |
Depreciation & Amortization (Cash Flow) | 1 | 2 | 2 | 2 | 2 |
Income After Depreciation & Amortization | -29 | -32 | -30 | -19 | -15 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 21.18 | 20.83 | 20.47 | 17.30 | 11.10 |
Diluted EPS Before Non-Recurring Items | -1.35 | -1.38 | -1.50 | -1.25 | -1.37 |
Diluted Net EPS (GAAP) | -1.35 | -1.38 | -1.50 | -1.25 | -1.37 |
Fiscal Year end for Profound Medical falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 2.23 | 1.91 | 2.01 | 1.73 | 1.60 |
Cost Of Goods | 0.80 | 0.64 | 0.95 | 0.67 | 0.55 |
Gross Profit | 1.44 | 1.27 | 1.06 | 1.06 | 1.05 |
SG&A, R&D, and Dept/Amort Expenses | 9.27 | 8.75 | 9.84 | 7.63 | 7.49 |
Income After SG&A, R&D, and Dept/Amort Expenses | -7.83 | -7.48 | -8.78 | -6.57 | -6.44 |
Non-Operating Income | 0.00 | 1.32 | -0.15 | 0.00 | 0.00 |
Interest Expense | -0.93 | 0.00 | 0.21 | -1.01 | 0.88 |
Pretax Income | -6.90 | -6.16 | -9.14 | -5.55 | -7.32 |
Income Taxes | 0.02 | 0.04 | -0.23 | 0.02 | 0.04 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -6.92 | -6.20 | -8.91 | -5.56 | -7.36 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -6.92 | -6.20 | -8.91 | -5.56 | -7.36 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 24.71 | 23.84 | 21.21 | 21.40 | 21.01 |
Diluted EPS Before Non-Recurring Items | -0.28 | -0.26 | -0.42 | -0.26 | -0.35 |
Diluted Net EPS (GAAP) | -0.28 | -0.26 | -0.42 | -0.26 | -0.35 |